Payment overview · 2025
General Payments
$266.01
8 reported records · 7 companies
Healthcare provider profile · identity verified
Donna Catanzaro, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SOMERSET, NJ · NPI 1306838578
Verified facts
What the public records show
CMS Open Payments records show Donna Catanzaro, MD received $266.01 in general payments during 2025 across 8 reported records.
ABBVIE INC. accounted for 43.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $115.03 | 43.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $42.15 | 15.8% | 2 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $29.93 | 11.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24.99 | 9.4% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.14 | 7.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.49 | 7.0% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.28 | 5.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $266.01 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $115.03 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $115.03 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $42.15 | 2 | 2025 |
Source payment records
|
|||||
| BIOFLO Normalized: bioflo |
Device | AngioDynamics, Inc. | $29.93 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $24.99 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $18.49 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
67 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 477 | 135 |
| Levothyroxine Sodium | Levothyroxine Sodium | 370 | 100 |
| Amlodipine Besylate | Amlodipine Besylate | 310 | 90 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 220 | 69 |
| Alprazolam | Alprazolam | 193 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 176 | 54 |
| Losartan Potassium | Losartan Potassium | 171 | 49 |
| Lisinopril | Lisinopril | 157 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 148 | 46 |
| Metformin Hcl | Metformin Hcl | 141 | 39 |
| Omeprazole | Omeprazole | 141 | 49 |
| Metformin Hcl Er | Metformin Hcl | 139 | 42 |
| Gabapentin | Gabapentin | 126 | 39 |
| Simvastatin | Simvastatin | 126 | 33 |
| Oxycodone Hcl | Oxycodone Hcl | 120 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 114 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 113 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 100 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 99 | 30 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 97 | 22 |
| Meloxicam | Meloxicam | 95 | 24 |
| Tramadol Hcl | Tramadol Hcl | 83 | 29 |
| Carvedilol | Carvedilol | 81 | 22 |
| Montelukast Sodium | Montelukast Sodium | 81 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 78 | 21 |
| Famotidine | Famotidine | 75 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 75 | 31 |
| Furosemide | Furosemide | 74 | 30 |
| Clonazepam | Clonazepam | 70 | 15 |
| Sertraline Hcl | Sertraline Hcl | 69 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 69 | 22 |
| Synthroid | Levothyroxine Sodium | 67 | 17 |
| Diazepam | Diazepam | 63 | 12 |
| Eliquis | Apixaban | 61 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 59 | 14 |
| Ozempic | Semaglutide | 58 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 58 | 17 |
| Lorazepam | Lorazepam | 56 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 55 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 52 | 14 |
| Valsartan | Valsartan | 52 | 17 |
| Bupropion Xl | Bupropion Hcl | 50 | 15 |
| Azelastine Hcl | Azelastine Hcl | 49 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 14 |
| Prednisone | Prednisone | 48 | 32 |
| Azithromycin | Azithromycin | 47 | 36 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 45 | 37 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 11 |
| Trazodone Hcl | Trazodone Hcl | 45 | 16 |
| Potassium Chloride | Potassium Chloride | 43 | 11 |
| Alendronate Sodium | Alendronate Sodium | 42 | 13 |
| Glimepiride | Glimepiride | 41 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | suppressed |
| Allopurinol | Allopurinol | 37 | suppressed |
| Atenolol | Atenolol | 37 | 11 |
| Linzess | Linaclotide | 35 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 32 | 14 |
| Mounjaro | Tirzepatide | 32 | suppressed |
| Aripiprazole | Aripiprazole | 31 | suppressed |
| Trulicity | Dulaglutide | 31 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 30 | 12 |
| Verapamil Er | Verapamil Hcl | 30 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Glipizide | Glipizide | 28 | suppressed |
| Jardiance | Empagliflozin | 28 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 28 | 17 |
| Ramipril | Ramipril | 28 | suppressed |
| Spironolactone | Spironolactone | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 25 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 25 | suppressed |
| Ketoconazole | Ketoconazole | 25 | 14 |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 23 | suppressed |
| Celecoxib | Celecoxib | 22 | 12 |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Nystatin | Nystatin | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Prolia | Denosumab | 20 | 11 |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Nexium | Esomeprazole Magnesium | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 16 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 16 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 16 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 13 |
| Metolazone | Metolazone | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Epinephrine | Epinephrine | 14 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 14 | suppressed |
| Lovaza | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Acthar | Corticotropin | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Ativan | Lorazepam | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Dayvigo | Lemborexant | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Easy Comfort Pen Needles | Pen Needle, Diabetic | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Jatenzo | Testosterone Undecanoate | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 11 |
| Santyl | Collagenase Clostridium Hist. | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Fluocinonide | Fluocinonide | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Rhopressa | Netarsudil Mesylate | 11 | suppressed |
| Vyzulta | Latanoprostene Bunod | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $266.01 · 8 records | ABBVIE INC. | BIOFLO, BREZTRI, CAPLYTA, Kerendia, PURIFIED CORTROPHIN GEL, QULIPTA, UBRELVY, ZORYVE | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error